BPA for pemazyre
Active Awarded Last action
- Contract number
- 36E79726A0008
- Awardee
-
Incyte Corporation UEI ZTM9U2G5VTK8
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 89% complete
- IDV ceiling
- $7,868,255.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Incyte Corporation has been awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) National Acquisition Center for the supply of Pemazyre (pemigatinib), an oncology pharmaceutical indicated for the treatment of specific cancer types. The contract, valued at $7.87 million, was awarded on December 3, 2025, with an ultimate completion date of December 2, 2026. This BPA represents a renewal or continuation of the existing $3.75 million single-award agreement and incorporates 2026 pricing updates in accordance with Public Law requirements. The contract operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) parent schedule and was awarded without set-aside provisions, indicating competition in the unrestricted federal marketplace. As the sole awardee, Incyte Corporation maintains significant incumbent advantage for supplying this specialized oncology medication to VA medical facilities across multiple Veterans Integrated Service Networks.
The BPA serves as an indefinite delivery vehicle enabling VA medical centers nationwide to efficiently procure Pemazyre tablets in multiple dosages (4.5 mg, 9 mg, and 13.5 mg) through pre-competed contract terms, eliminating the need for repetitive solicitations. This arrangement supports the VA's strategic objective of providing consistent access to innovative oncology treatments for eligible veterans while leveraging the Federal Supply Schedule framework to ensure compliance with federal pricing and contracting regulations. By consolidating pharmaceutical procurement through this BPA structure, the VA optimizes procurement efficiency and ensures predictable supply chain management for this critical cancer treatment across its healthcare network.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79726A0008?
36E79726A0008 was awarded to Incyte Corporation by National Acquisition Center (Headquarters) on December 3, 2025.
How much is contract 36E79726A0008 worth?
36E79726A0008's own ceiling is $7,868,255.
Who can order from contract 36E79726A0008?
36E79726A0008 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79726A0008 under another contract?
Yes. 36E79726A0008 is a blanket purchase agreement under 36F79720D0189, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79726A0008 competed?
The extent of competition for 36E79726A0008 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV